ПОСЛЕДНИЕ ДОСТИЖЕНИЯ В ЛЕЧЕНИИ ХРОНИЧЕСКОГО ГЕПАТИТА В: С ЧЕГО НАЧИНАТЬ СТАРТОВУЮ ТЕРАПИЮ?
https://doi.org/10.22625/2072-6732-2011-3-4-18-25
Аннотация
В настоящем обзоре обобщены последние достижения в исследовании эффективности и безопасности противовирусной терапии больных хроническим гепатитом В. Описана современная концепция мониторинга и лечения этих пациентов. Особое внимание уделено прогностическому значению определения уровня НВsАgна этапах контроля лечения. Представлены новые алгоритмы интерферонотерапии и подходы к лечению аналогами нуклеоз(т)идов. Предложено начинать стартовую терапию больных хроническим гепатитом В с пегилированных интерферонов.При отсутствии благоприятных прогностических критериев достижения устойчивого иммунного контроля, а также наличия противопоказаний к интерферонотерапии и развитии нежелательных явлений, требующих ее отмены, пациентов необходимо переводить на лечение нуклеоз(т)идными аналогами.
Об авторе
К. В. Жданов
Военно-медицинская академия имени С.М. Кирова, Санкт-Петербург
Россия
Россия
начальник кафедры инфекционных болезней Военно-медицинской академии им. С.М. Кирова, д.м.н., профессор, тел. 8 (812)542-92-14
Список литературы
1. EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association For The Study Of The Liver // J. Hepatol. – 2009. – V. 50, № 2. – P. 227–242.
2. Lampertico, P. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24- onth interferon therapy / P. Lampertico [et al.] // Hepatology. – 2003. – V. 37, № 4. – P. 756–763.
3. Moucari, R. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study / R. Moucari [et al.] // J. Hepatol. – 2009. – V. 50, № 6. – P. 1084–1092.
4. Lin, S.M. Interferon therapyin HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma / S.M. Lin [et al.] // J. Hepatol. – 2007. – V. 46, № 1. – P. 45–52.
5. Marcellin, P. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B / P. Marcellin [et al.] // N. Engl. J. Med. – 2004. – V. 351. – P. 1206–1217.
6. Lau, G.K. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B /G.K. Lau [et al.] // N. Engl. J. Med. – 2005. – V. 352, № 26. – P. 2682–2695.
7. Janssen, H.L. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial / H.L. Janssen [et al.] // Lancet. – 2005. – V. 365, № 9454. – P. 123–129.
8. Chan, H.L. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferonalpha2b and lamivudine with lamivudine alone / H.L. Chan [et al.] // Ann Intern Med. – 2005. – V. 142, № 4. – P. 240–250.
9. Wong, V.W. How Durable Is Peginterferon Therapy in Hepatitis B e Antigen–Positive Patients? / V.W. Wong //Hepatology. – 2010. – Vl. 51. – P. 1945
10. Buster, E.H. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b / E.H. Buster [et al.] // Gastroenterology. – 2008. – V.135, № 2. – P. 459–467.
11. Marcellin, P. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a / P. Marcellin [et al.] //Gastroenterology. – 2009. – V.136, № 7. – P. 2169–2179. – E. 1–4.
12. Buster, E.H. Factors that Predict Response of Patients with Hepatitis Be Antigen-Positive Chronic Hepatitis B to Peginterferon-alpha / E.H. Buster [et al.] // Gastroenterology. – 2009. – V. 137, № 6. – P. 2002–2009.
13. Нурмухаметова, Е.А. Генотипы вируса гепатита В: потенциальное клиническое значение / Е.А. Нурмухаметова, Н.П. Блохина // Фарматека. – 2008. – Т. 156, № 2. – С. 33–35.
14. Lampertico, P. PEGBELIVER STUDY: HBsAg decline at week 24 of extendet peginterferon alfa-2a (PEG-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotipe D patients / P. Lampertico [et al.] // J. Hepatol. – 2011. – V. 54 (suppl. 1), – P. S293.
15. Rijckborst, V. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis В using HBsAg and HBV DNA levels / V. Rijckborst [et al.] // Hepatology. – 2010. – V. 52. – P 454–461.
16. Brunetto, M.R. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B / M.R. Brunetto [et al.] // Hepatology. – 2009. – V. 49, № 4. – P. 1141–1150.
17. Moucari, R. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients / R. Moucari [et al.] // Hepatology. – 2009. – V. 49, № 4. – P. 1151–1157.
18. Piratvisuth, T. On-treatment decline in serum HBsAg levels predicts sustained immune control 6 months posttreatment and subsequent HBsAg clearance in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alfa-2a [40KD] (PEGASYS) / T. Piratvisuth [et al.] //Hepatol Int. – 2010. – V. 4. – P. 152, abstract PP211.
19. Gane, E. NEPTUNE STUDY: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon ALFA-2a IN HBeAg-positive patients / E. Gane [et al.] // J. Hepatol. – 2011. – In Press.
20. Marcellin P. On-treatment decline in serum HBsAg levels predicts sustained immune control 6 months post-treatment and subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a [40KD] (PEGASYS) / P. Marcellin [et al.] //Hepatol Int. – 2010. – V. 4. – P. 151, abstract PP209.
21. Rijckborst, V. Early prediction of sustained response to peginterferon alfa-2a in HBeAg-negative patients: the role of on-treatment HBsAg and HBV DNA levels. / V. Rijckborst [et al.] // J. Hepatol. – 2010. – V. 52, suppl. 1. – P. A8
22. Milan, J. Chronic hepatitis B: peginterferon or nucleos(t) ide analogues / J. Milan, L.A. Janssen // Liver Int. – 2011. – V. 31 (supl.1). – P. 78–84.
23. Moucari, R. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks. / R. Moucari // Gastroenterol Hepatol. – 2010. – V. 25. – P. 1474–1475.
24. Moucari, R. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B / R. Moucari, P. Marcellin // Liver Int. – 2011. – V. 31 (supl. 1). – P.122–128.
25. Sonneveld, M.J. Prediction of sustained response to peginterferon alfa-2b for hepatitis В e antigen-positive chronic hepatitis В using on-treatment hepatitis В surface antigen decline / M.J. Sonneveld [et al.] // Hepatology. – 2010. – V. 52. – P. 1251–1257.
26. Chang, T.T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B; BEHoLD AI463022 Study Group / T.T. Chang [et al.] // N. Engl. J. Med. – 2006. – V.354, № 10. – P. 1001–1010.
27. Lai, C.L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B; BEHoLD AI463027 Study Group / C.L. Lai [et al.] // N. Engl. J. Med. – 2006. – V. 354, № 10. – P. 1011–1020.
28. Gish, R.G. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B / R.G. Gish //Gastroenterology. – 2007. – V. 133. – P. 1437–1444.
29. Lai, C.L. Telbivudine versus lamivudine in patients with chronic hepatitis B / C.L. Lai, E. Gane , Y.F. Liaw и соавт. // N. Engl. J. Med. – 2007. – V. 357. – P. 2576–2588.
30. Liaw, Y.F. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B; GLOBE Study Group / Y.F. Liaw [et al.] // Gastroenterology. – 2009. – V. 136, № 2. – P. 486–495.
31. Zeuzem, S. Baseline characteristics and early ontreatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B / S. Zeuzem [et al.] // J. Hepatol. – 2009. – V. 51, № 1. – P. 11–20.
32. Hou, J. Five-year telbivudine treatment with effective viral suppression results in resolution of liver inflammations and fibrosis regression in patients with chronic hepatitis B / J. Hou [et al.] // J. Hepatol. – 2011. – V. 54 (suppl. 1), – P. S287.
33. Heathcote, E.J. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. / E.J. Heathcote [et al.] // Gastroenterology. – 2011. – V. 140, № 1. – P. 132–143.
34. Marcellin, P. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B / P. Marcellin [et al.] // N. Engl. J. Med. – 2008. – V. 359, № 23. – P. 2442–2455.
35. Piratvisuth, T. 1-Year Results of Telbivudine Roadmap Study Demonstrated MaximizingAntiviral Efficacy and Minimizing Resistance in HBeAg Positive Chronic Hepatitis B Patients / T. Piratvisuth [et al.] // Hepatol. Int. – 2011. - V. 5, № 1. – P. 18–19
36. Shouval, D. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy / D. Shouval [et al.] // J. Hepatol. – 2009. – V. 50, №2. – Р. 289–295.
37. Liaw, Y. Impact of hepatitis B therapy on the long-term outcome of liver disease / Y. Liaw // Liver Int. – 2011. – V. 31 (supl. 1). – P. 117–121.
38. Liaw, Y.F. Lamivudine for patients with chronic hepatitis В and advanced liver disease / Y.F. Liaw, J.J.Y. Sung // N Engl. Med. – 2004. – V. 351. –P. 1521–1531.
39. Dienstag, J.L. Histological outcome during long-term lamivudine therapy / J.L. Dienstag [et al.] // Gastroenterology. – 2003. – V. 124. – P. 105–117.
40. Hadziyannis, S.J. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years / S.J. Hadziyannis [et al.] // Gastroenterology. – 2006. – V.131, № 6. – P. 1743–1751.
41. Marcellin, P. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis В е antigen-positive chronic hepatitis B / P. Marcellin [et al.] // Hepatology. – 2008. – V. 48. – P. 750–758.
42. Yokosuka, O. Long-term use of entecavir in nucleosidenaive Japanese patients with chronic hepatitis В infection / O. Yokosuka [et al.] // Hepatol. – 2010. – V. 52. –P. 791–799.
43. Chang, T.T. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis В patients / T.T. Chang [et al.] // Hepatology. – 2010. – V. 52. – P. 886–893.
44. Heathcote, E.J. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B / E.J. Heathcote [et al.] // Gastroenterology. – 2011. – V. 140, № 1. – P. 132–143.
45. Zoutendijk, R. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss./ R. Zoutendijk [et al.] // J. Infect. Dis. – 2011. – V. 204, № 3. – P. 415–418.
46. Rajendra, A. Economics of chronic hepatitis B and hepatitis C / A. Rajendra, J.B. Wong // J . Hepatol. – 2007. –V. 47, № 4. – P. 608–617.
47. Chevaliez, S. Virological characteristics of a large prospective cohort of patient with chronic hepatitis B newly seen in hepatology reference centers in France in 2008–2010 / S. Chevaliez [et al.] // J. Hepatol. – 2011. – V. 54 (suppl. 1), – P. 146
48. Wursthorn, K. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients / K. Wursthorn [et al.] // Hepatology. – 2010. – V. 52, № 5. – P. 1611–1620.
Рецензия
Для цитирования:
Жданов К.В. ПОСЛЕДНИЕ ДОСТИЖЕНИЯ В ЛЕЧЕНИИ ХРОНИЧЕСКОГО ГЕПАТИТА В: С ЧЕГО НАЧИНАТЬ СТАРТОВУЮ ТЕРАПИЮ? Журнал инфектологии. 2011;3(4):18-25. https://doi.org/10.22625/2072-6732-2011-3-4-18-25
For citation:
Zhdanov K.V. Recent advances in the treatment of chronic hepatitis B: where to start initial therapy? Journal Infectology. 2011;3(4):18-25. (In Russ.) https://doi.org/10.22625/2072-6732-2011-3-4-18-25
Просмотров: 554
.png)
.png)
Послать статью по эл. почте 